Literature DB >> 10968781

Therapeutic approaches to bone diseases.

G A Rodan1, T J Martin.   

Abstract

The strength and integrity of our bones depends on maintaining a delicate balance between bone resorption by osteoclasts and bone formation by osteoblasts. As we age or as a result of disease, this delicate balancing act becomes tipped in favor of osteoclasts so that bone resorption exceeds bone formation, rendering bones brittle and prone to fracture. A better understanding of the biology of osteoclasts and osteoblasts is providing opportunities for developing therapeutics to treat diseases of bone. Drugs that inhibit the formation or activity of osteoclasts are valuable for treating osteoporosis, Paget's disease, and inflammation of bone associated with rheumatoid arthritis or periodontal disease. Far less attention has been paid to promoting bone formation with, for example, growth factors or hormones, an approach that would be a valuable adjunct therapy for patients receiving inhibitors of bone resorption.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10968781     DOI: 10.1126/science.289.5484.1508

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  401 in total

1.  Local and systemic control of the osteoblast.

Authors:  G J Strewler
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 2.  Manipulating the environment of cancer cells in bone: a novel therapeutic approach.

Authors:  T John Martin
Journal:  J Clin Invest       Date:  2002-11       Impact factor: 14.808

3.  Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone.

Authors:  Jivan N Yewle; David A Puleo; Leonidas G Bachas
Journal:  Bioconjug Chem       Date:  2011-12-05       Impact factor: 4.774

4.  Stat1 functions as a cytoplasmic attenuator of Runx2 in the transcriptional program of osteoblast differentiation.

Authors:  Sunhwa Kim; Takako Koga; Miho Isobe; Britt E Kern; Taeko Yokochi; Y Eugene Chin; Gerard Karsenty; Tadatsugu Taniguchi; Hiroshi Takayanagi
Journal:  Genes Dev       Date:  2003-08-15       Impact factor: 11.361

Review 5.  Information-based methods in the development of antiparasitic drugs.

Authors:  Kristina Wolf; Matthias Dormeyer
Journal:  Parasitol Res       Date:  2002-12-04       Impact factor: 2.289

6.  RANK ligand and the regulation of skeletal remodeling.

Authors:  Norman H Bell
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

Review 7.  Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.

Authors:  Scott P Nichols; Wesley L Storm; Ahyeon Koh; Mark H Schoenfisch
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

8.  Integrated model for denosumab and ibandronate pharmacodynamics in postmenopausal women.

Authors:  Dhananjay D Marathe; Anshu Marathe; Donald E Mager
Journal:  Biopharm Drug Dispos       Date:  2011-09-22       Impact factor: 1.627

9.  Phytoestrogens regulate mRNA and protein levels of guanine nucleotide-binding protein, beta-1 subunit (GNB1) in MCF-7 cells.

Authors:  Srivatcha Naragoni; Shireesha Sankella; Kinesha Harris; Wesley G Gray
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

Review 10.  Semaphorin 3A: A new player in bone remodeling.

Authors:  Ren Xu
Journal:  Cell Adh Migr       Date:  2013-01-01       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.